Antibe Therapeutics released positive secondary endpoint data from the recent Phase 2B Gastrointestinal safety study for its lead drug, ATB-346. These results are consistent with the primary endpoint data, previously released in March 2018.
Advanced Code injection
Antibe Therapeutics released positive secondary endpoint data from the recent Phase 2B Gastrointestinal safety study for its lead drug, ATB-346. These results are consistent with the primary endpoint data, previously released in March 2018.